Ji Rui, Ren Qian, Bai Suyang, Wang Yuping, Zhou Yongning
Department of Gastroenterology, the First Hospital of Lanzhou University Key Laboratory for Gastrointestinal Diseases of Gansu Province, Lanzhou University, Lanzhou, China.
Medicine (Baltimore). 2018 Jun;97(25):e10824. doi: 10.1097/MD.0000000000010824.
The high pretreatment plasma fibrinogen has been widely reported to be a possible biomarker for predicting prognosis in hepatocellular carcinoma (HCC) and pancreatic carcinoma (PC), but persuasive conclusion has not been made yet. Thus, we herein conducted a meta-analysis to comprehensively assess the prognostic value of high pretreatment plasma fibrinogen in patients with HCC and PC.
We systematically searched PubMed, EMBASE, and Web of Science to identify eligible studies from inception to November 10, 2017.
Finally, a total of 12 publications with 13 studies were included. Of these eligible studies, 5 publications with 6 studies were about pancreatic cancer and 7 were about HCC. The pooled analysis indicated that high plasm fibrinogen level was significantly related to worse overall survival (OS) in HCC [hazard ratio (HR) = 1.87; 95% confidence interval (CI): 1.55-2.24; P < .01]. Similarly, from our result, it was found that high plasm fibrinogen was also significantly associated with worse OS in PC (HR = 1.56; 95% CI: 1.13-2.15; P < .01).
Taken together, our meta-analysis confirmed that high plasma fibrinogen level could predict worse survival in HCC and PC.
预处理时血浆纤维蛋白原水平高已被广泛报道可能是预测肝细胞癌（HCC）和胰腺癌（PC）预后的生物标志物，但尚未得出有说服力的结论。因此，我们在此进行一项荟萃分析，以全面评估预处理时血浆纤维蛋白原水平高对HCC和PC患者的预后价值。
我们系统检索了PubMed、EMBASE和科学网，以确定从数据库建立至2017年11月10日的符合条件的研究。
最终，共纳入12篇文献中的13项研究。在这些符合条件的研究中，5篇文献中的6项研究是关于胰腺癌的，7项是关于HCC的。汇总分析表明，高血浆纤维蛋白原水平与HCC患者较差的总生存期（OS）显著相关[风险比（HR）=1.87；95%置信区间（CI）：1.55 - 2.24；P <.01]。同样，从我们的结果中发现，高血浆纤维蛋白原水平也与PC患者较差的OS显著相关（HR = 1.56；95% CI：1.13 - 2.15；P <.01）。
综上所述，我们的荟萃分析证实，高血浆纤维蛋白原水平可预测HCC和PC患者较差的生存期。
